Elevated concentrations of neurofilament light chain in the cerebrospinal fluid of bipolar disorder patients

Neuropsychopharmacology

Volumn 39, Issue 10, 2014, Pages 2349-2356

  Jakobsson, Joel ^a   Bjerke, Maria ^a   Ekman, Carl Johan ^b   Sellgren, Carl ^b   Johansson, Anette G M ^b   Zetterberg, Henrik ^a,c   Blennow, Kaj ^a   Landén, Mikael ^a,b  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; FATTY ACID BINDING PROTEIN; HEART TYPE FATTY ACID BINDING PROTEIN; LAMOTRIGINE; LITHIUM; MYELIN BASIC PROTEIN; NEUROFILAMENT PROTEIN; NEUROFILAMENT PROTEIN LIGHT CHAIN; PROTEIN S100B; UNCLASSIFIED DRUG; VALPROATE SEMISODIUM; BIOLOGICAL MARKER; FABP3 PROTEIN, HUMAN; LITHIUM DERIVATIVE; MBP PROTEIN, HUMAN; NEUROFILAMENT PROTEIN L; NEUROLEPTIC AGENT; PSYCHOTROPIC AGENT; S100B PROTEIN, HUMAN; TRIAZINE DERIVATIVE;

ADULT; ARTICLE; BIPOLAR DISORDER; BIPOLAR I DISORDER; BIPOLAR II DISORDER; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; LIGHT CHAIN; MAJOR CLINICAL STUDY; MALE; NERVE CELL LESION; NEUROPATHOLOGY; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PSYCHIATRIC DIAGNOSIS; AGE; BRAIN; CEREBROSPINAL FLUID; MIDDLE AGED; NERVE FIBER; PATHOLOGY; PSYCHOLOGICAL RATING SCALE; SEX DIFFERENCE; STATISTICAL MODEL;

ADULT; AGE FACTORS; ANTIPSYCHOTIC AGENTS; AXONS; BIOLOGICAL MARKERS; BIPOLAR DISORDER; BRAIN; FATTY ACID-BINDING PROTEINS; FEMALE; HUMANS; LINEAR MODELS; LITHIUM COMPOUNDS; MALE; MIDDLE AGED; MYELIN BASIC PROTEIN; NEUROFILAMENT PROTEINS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTROPIC DRUGS; S100 CALCIUM BINDING PROTEIN BETA SUBUNIT; SEX FACTORS; TRIAZINES;

EID: 84906317738     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2014.81     Document Type: Article

References (51)

1. Altshuler LL, Curran JG, Hauser P, Mintz J, Denicoff K, Post R (1995). T2 hyperintensities in bipolar disorder: Magnetic resonance imaging comparison and literature meta-Analysis. Am J Psychiatry 152: 1139-1144
2. Andreazza AC, Cassini C, Rosa AR, Leite MC, de Almeida LM, Nardin P et al (2007). Serum S100B and antioxidant enzymes in bipolar patients. J Psychiatr Res 41: 523-529
3. Belmaker RH (2004). Bipolar disorder. N Engl J Med 351: 476-486
4. Beyer JL, Young R, Kuchibhatla M, Krishnan KR (2009). Hyperintense MRI lesions in bipolar disorder: A meta-Analysis and review. Int Rev Psychiatry 21: 394-409
5. Bjerke M, Andreasson U, Rolstad S, Nordlund A, Lind K, Zetterberg H et al (2009). Subcortical vascular dementia biomarker pattern in mild cognitive impairment. Dement Geriatr Cogn Disord 28: 348-356
6. Bjerke M, Zetterberg H, Edman A, Blennow K, Wallin A, Andreasson U (2011). Cerebrospinal fluid matrix metalloproteinases and tissue inhibitor of metalloproteinases in combination with subcortical and cortical biomarkers in vascular dementia and Alzheimer's disease. J Alzheimers Dis 27: 665-676
7. Bolandzadeh N, Davis JC, Tam R, Handy TC, Liu-Ambrose T (2012). The association between cognitive function and white matter lesion location in older adults: A systematic review. BMC Neurol 12: 126
8. Brettschneider J, Petzold A, Schottle D, Claus A, Riepe M, Tumani H (2006). The neurofilament heavy chain (NfH) in the cerebrospinal fluid diagnosis of Alzheimer's disease. Dement Geriatr Cogn Disord 21: 291-295
9. Cha DS, McIntyre RS (2012). Treatment-emergent adverse events associated with atypical antipsychotics. Expert Opin Pharmacother 13: 1587-1598
10. Chui HC (2007). Subcortical ischemic vascular dementia. Neurol Clin 25: 717-740
11. Davis KA, Kwon A, Cardenas VA, Deicken RF (2004). Decreased cortical gray and cerebral white matter in male patients with familial bipolar I disorder. J Affect Disord 82: 475-485
12. Ekman CJ, Lind J, Ryden E, Ingvar M, Landen M (2010). Manic episodes are associated with grey matter volume reduction-A voxel-based morphometry brain analysis. Acta Psychiatr Scand 122: 507-515
13. Ekman M, Granstrom O, Omerov S, Jacob J, Landen M (2013). The societal cost of bipolar disorder in Sweden. Soc Psychiatry Psychiatr Epidemiol 48: 1601-1610
14. Gunnarsson M, Malmestrom C, Axelsson M, Sundstrom P, Dahle C, Vrethem M et al (2011). Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab. Ann Neurol 69: 83-89
15. Ho BC, Andreasen NC, Ziebell S, Pierson R, Magnotta V (2011). Long-Term antipsychotic treatment and brain volumes: A longitudinal study of first-episode schizophrenia. Arch Gen Psychiatry 68: 128-137
16. Jakobsson J, Zetterberg H, Blennow K, Ekman CJ, Johansson AG, Landen M (2013). Altered concentrations of amyloid precursor protein metabolites in the cerebrospinal fluid of patients with bipolar disorder. Neuropsychopharmacology 38: 664-672
17. Kapoor R, Furby J, Hayton T, Smith KJ, Altmann DR, Brenner R et al (2010). Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: A randomised, double-blind, placebocontrolled, parallel-group trial. Lancet Neurol 9: 681-688
18. Kempton MJ, Geddes JR, Ettinger U, Williams SC, Grasby PM (2008). Meta-Analysis, database, and meta-regression of 98 structural imaging studies in bipolar disorder. Arch Gen Psychiatry 65: 1017-1032
19. Kieseppa T, van Erp TG, Haukka J, Partonen T, Cannon TD, Poutanen VP et al (2003). Reduced left hemispheric white matter volume in twins with bipolar I disorder. Biol Psychiatry 54: 896-905
20. Konarski JZ, McIntyre RS, Kennedy SH, Rafi-Tari S, Soczynska JK, Ketter TA (2008). Volumetric neuroimaging investigations in mood disorders: Bipolar disorder versus major depressive disorder. Bipolar Disord 10: 1-37
21. Krishnan MS, O'Brien JT, Firbank MJ, Pantoni L, Carlucci G, Erkinjuntti T et al (2006). Relationship between periventricular and deep white matter lesions and depressive symptoms in older people. The LADIS Study. Int J Geriatr Psychiatry 21: 983-989
22. Kupfer DJ (2005). The increasing medical burden in bipolar disorder. JAMA 293: 2528-2530
23. Lu CH, Petzold A, Kalmar B, Dick J, Malaspina A, Greensmith L (2012). Plasma neurofilament heavy chain levels correlate to markers of late stage disease progression and treatment response in SOD1(G93A) mice that model ALS. PLoS One 7: E40998
24. Machado-Vieira R, Lara DR, Portela LV, Goncalves CA, Soares JC, Kapczinski F et al (2002). Elevated serum S100B protein in drugfree bipolar patients during first manic episode: A pilot study. Eur Neuropsychopharmacol 12: 269-272
25. Martinez-Aran A, Vieta E, Colom F, Reinares M, Benabarre A, Gasto C et al (2000). Cognitive dysfunctions in bipolar disorder: Evidence of neuropsychological disturbances. Psychother Psychosom 69: 2-18
26. Martinez-Aran A, Vieta E, Colom F, Torrent C, Reinares M, Goikolea JM et al (2005). Do cognitive complaints in euthymic bipolar patients reflect objective cognitive impairment? Psychother Psychosom 74: 295-302
27. McDonald C, Zanelli J, Rabe-Hesketh S, Ellison-Wright I, Sham P, Kalidindi S et al (2004). Meta-Analysis of magnetic resonance imaging brain morphometry studies in bipolar disorder. Biol Psychiatry 56: 411-417
28. Merikangas KR, Jin R, He JP, Kessler RC, Lee S, Sampson NA et al (2011). Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry 68: 241-251
29. Minden SL, Schiffer RB (1990). Affective disorders in multiple sclerosis. Review and recommendations for clinical research. Arch Neurol 47: 98-104
30. Moore GJ, Bebchuk JM, Wilds IB, Chen G, Manji HK (2000). Lithium-induced increase in human brain grey matter. Lancet 356: 1241-1242
31. Olsson B, Zetterberg H, Hampel H, Blennow K (2011). Biomarkerbased dissection of neurodegenerative diseases. Prog Neurobiol 95: 520-534
32. Palsson E, Figueras C, Johansson AG, Ekman CJ, Hultman B, Ostlind J et al (2013). Neurocognitive function in bipolar disorder: A comparison between bipolar I and II disorder and matched controls. BMC Psychiatry 13: 165
33. Pelsers MM, Hanhoff T, Van Der Voort D, Arts B, Peters M, Ponds R et al (2004). Brain-And heart-Type fatty acid-binding proteins in the brain: Tissue distribution and clinical utility. Clin Chem 50: 1568-1575
34. Perlis RH (2011). Translating biomarkers to clinical practice. Mol Psychiatry 16: 1076-1087
35. Perrot R, Berges R, Bocquet A, Eyer J (2008). Review of the multiple aspects of neurofilament functions, and their possible contribution to neurodegeneration. Mol Neurobiol 38: 27-65
36. Rajkowska G, Miguel-Hidalgo JJ (2007). Gliogenesis and glial pathology in depression. CNS Neurol Disord Drug Targets 6: 219-233
37. Robinson LJ, Thompson JM, Gallagher P, Goswami U, Young AH, Ferrier IN et al (2006). A meta-Analysis of cognitive deficits in euthymic patients with bipolar disorder. J Affect Disord 93: 105-115
38. Rosengren LE, Karlsson JE, Karlsson JO, Persson LI, Wikkelso C (1996). Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF. J Neurochem 67: 2013-2018
39. Rosso IM, Killgore WD, Cintron CM, Gruber SA, Tohen M, Yurgelun-Todd DA (2007). Reduced amygdala volumes in firstepisode bipolar disorder and correlation with cerebral white matter. Biol Psychiatry 61: 743-749
40. Ryden E, Thase ME, Straht D, Aberg-Wistedt A, Bejerot S, Landen M (2009). A history of childhood attention-deficit hyperactivity disorder (ADHD) impacts clinical outcome in adult bipolar patients regardless of current ADHD. Acta Psychiatr Scand 120: 239-246
41. Salzer J, Svenningsson A, Sundstrom P (2010). Neurofilament light as a prognostic marker in multiple sclerosis. Mult Scler 16: 287-292
42. Sanchez-Moreno J, Martinez-Aran A, Colom F, Scott J, Tabares-Seisdedos R, Sugranyes G et al (2009). Neurocognitive dysfunctions in euthymic bipolar patients with and without prior history of alcohol use. J Clin Psychiatry 70: 1120-1127
43. Schroeter ML, Abdul-Khaliq H, Diefenbacher A, Blasig IE (2002). S100B is increased in mood disorders and may be reduced by antidepressive treatment. Neuroreport 13: 1675-1678
44. Schroeter ML, Abdul-Khaliq H, Krebs M, Diefenbacher A, Blasig IE (2008). Serum markers support disease-specific glial pathology in major depression. J Affect Disord 111: 271-280
45. Schroeter ML, Sacher J, Steiner J, Schoenknecht P, Mueller K (2013). Serum S100B represents a new biomarker for mood disorders. Curr Drug Targets 14: 1237-1248
46. Sjogren M, Rosengren L, Minthon L, Davidsson P, Blennow K, Wallin A (2000). Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD. Neurology 54: 1960-1964
47. Strakowski SM, Wilson DR, Tohen M, Woods BT, Douglass AW, Stoll AL (1993). Structural brain abnormalities in first-episode mania. Biol Psychiatry 33: 602-609
48. Whitaker JN, Lisak RP, Bashir RM, Fitch OH, Seyer JM, Krance R et al (1980). Immunoreactive myelin basic protein in the cerebrospinal fluid in neurological disorders. Ann Neurol 7: 58-64
49. Yatham LN, Kennedy SH, Schaffer A, Parikh SV, Beaulieu S, O'Donovan C et al (2009). Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: Update 2009. Bipolar Disord 11: 225-255
50. Zarate CA Jr, Tohen M, Land M, Cavanagh S (2000). Functional impairment and cognition in bipolar disorder. Psychiatr Q 71: 309-329
51. Zetterberg H, Jacobsson J, Rosengren L, Blennow K, Andersen PM (2007). Cerebrospinal fluid neurofilament light levels in amyotrophic lateral sclerosis: Impact of SOD1 genotype. Eur J Neurol 14: 1329-1333